And yes we_老虎社区_美港股上老虎

XLMM
2022-01-12

And yes we have one of them today...South Korea! Yay!

Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>

On Monday, Stanley Erck, the CEO of Novavax said he expects the company's coronavirus vaccine could

Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":694641100,"tweetId":"694641100","gmtCreate":1641969883226,"gmtModify":1641969883316,"author":{"id":4100909250192760,"idStr":"4100909250192760","authorId":4100909250192760,"authorIdStr":"4100909250192760","name":"XLMM","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body>And yes we have one of them today...South Korea! Yay!</body></html>","htmlText":"<html><head></head><body>And yes we have one of them today...South Korea! Yay!</body></html>","text":"And yes we have one of them today...South Korea! Yay!","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/694641100","repostId":1192824861,"repostType":2,"repost":{"id":"1192824861","kind":"news","pubTimestamp":1641897395,"share":"https://www.laohu8.com/m/news/1192824861?lang=zh_CN&edition=full","pubTime":"2022-01-11 18:36","market":"us","language":"en","title":"Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1192824861","media":"Seeking Alpha","summary":"On Monday, Stanley Erck, the CEO of Novavax said he expects the company's coronavirus vaccine could","content":"<html><head></head><body>On Monday, Stanley Erck, the CEO of <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> said he expects the company&#39;s coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.<blockquote><html><head></head><body>周一，Stanley Erck，首席执行官<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>他表示，他预计该公司的冠状病毒疫苗可能会在未来几个月内在包括美国在内的多个国家获得使用许可。</body></html></blockquote>The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.<blockquote>这家美国疫苗制造商已向10个不同的监管机构申请紧急批准。“我预计在接下来的90天内我们可以拥有全部10个，”Erck说。</blockquote>On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.<blockquote>12月31日，Novavax向FDA提交了最终数据包。它尚未提交紧急使用授权的完整申请，但很快就会提交，并预计美国监管机构将在二月份做出决定。</blockquote>Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.<blockquote>Erck没有透露其他监管机构的名称，但根据该公司网站，它最近已在日本、阿联酋、新加坡、新西兰、加拿大、澳大利亚、南非和英国申请批准。</blockquote>Several other health agencies across the globe have already given their nod of approval to the vaccine.<blockquote>全球其他几个卫生机构已经批准了这种疫苗。</blockquote>Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.<blockquote>此外，周一，辉瑞(NYSE：PFE)首席执行官Albert Bourla表示，该公司的两剂疫苗可能无法对奥密克戎新冠病毒变种提供强有力的保护，而且最初的疫苗也失去了一些预防住院的功效。</blockquote>In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.<blockquote>在摩根大通医疗保健会议上接受采访时，布尔拉强调了第三次注射对于增强人们对奥密克戎病毒的保护的重要性。</blockquote>“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”<blockquote>“这两剂对奥密克戎来说还不够，”布尔拉说。“当前疫苗的第三剂在防止死亡方面提供了相当好的保护，并在防止住院方面提供了良好的保护。”</blockquote>Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.<blockquote>早些时候，辉瑞首席执行官表示，该公司将在三月份准备好一种针对奥密克戎的疫苗，但他表示尚不清楚是否需要它。</blockquote>Bourla also said he didn&#39;t know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.<blockquote>布尔拉还表示，他不知道是否需要第四次疫苗注射，但应该研究这种可能性，以找到对抗病毒的最佳方法。</blockquote></body></html><blockquote></blockquote>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovavax COVID-19 vaccine could be cleared in multiple countries: CEO Stanley Erck<blockquote>Novavax COVID-19疫苗可能在多个国家获得批准：首席执行官Stanley Erck</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nSeeking Alpha2022-01-11 18:36\n\n</h4>\n</header>\n<article>\n<html><head></head><body>On Monday, Stanley Erck, the CEO of <a href=\"https://laohu8.com/S/NVAX\">Novavax </a> said he expects the company&#39;s coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.<blockquote><html><head></head><body>周一，Stanley Erck，首席执行官<a href=\"https://laohu8.com/S/NVAX\">Novavax</a>他表示，他预计该公司的冠状病毒疫苗可能会在未来几个月内在包括美国在内的多个国家获得使用许可。</body></html></blockquote>The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.<blockquote>这家美国疫苗制造商已向10个不同的监管机构申请紧急批准。“我预计在接下来的90天内我们可以拥有全部10个，”Erck说。</blockquote>On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.<blockquote>12月31日，Novavax向FDA提交了最终数据包。它尚未提交紧急使用授权的完整申请，但很快就会提交，并预计美国监管机构将在二月份做出决定。</blockquote>Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.<blockquote>Erck没有透露其他监管机构的名称，但根据该公司网站，它最近已在日本、阿联酋、新加坡、新西兰、加拿大、澳大利亚、南非和英国申请批准。</blockquote>Several other health agencies across the globe have already given their nod of approval to the vaccine.<blockquote>全球其他几个卫生机构已经批准了这种疫苗。</blockquote>Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.<blockquote>此外，周一，辉瑞(NYSE：PFE)首席执行官Albert Bourla表示，该公司的两剂疫苗可能无法对奥密克戎新冠病毒变种提供强有力的保护，而且最初的疫苗也失去了一些预防住院的功效。</blockquote>In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.<blockquote>在摩根大通医疗保健会议上接受采访时，布尔拉强调了第三次注射对于增强人们对奥密克戎病毒的保护的重要性。</blockquote>“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”<blockquote>“这两剂对奥密克戎来说还不够，”布尔拉说。“当前疫苗的第三剂在防止死亡方面提供了相当好的保护，并在防止住院方面提供了良好的保护。”</blockquote>Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.<blockquote>早些时候，辉瑞首席执行官表示，该公司将在三月份准备好一种针对奥密克戎的疫苗，但他表示尚不清楚是否需要它。</blockquote>Bourla also said he didn&#39;t know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.<blockquote>布尔拉还表示，他不知道是否需要第四次疫苗注射，但应该研究这种可能性，以找到对抗病毒的最佳方法。</blockquote></body></html><blockquote></blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://seekingalpha.com/news/3786944-novavax-covid-19-vaccine-could-be-cleared-in-multiple-countries-in-90-days-ceo-stanley-erck\">Seeking Alpha</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVAX":"诺瓦瓦克斯医药"},"source_url":"https://seekingalpha.com/news/3786944-novavax-covid-19-vaccine-could-be-cleared-in-multiple-countries-in-90-days-ceo-stanley-erck","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1192824861","content_text":"On Monday, Stanley Erck, the CEO of Novavax said he expects the company's coronavirus vaccine could be cleared for use in multiple countries, including U.S., in coming months.The U.S. vaccine maker has filed for emergency approval with 10 different regulatory agencies. “I expect in the next 90 days we could have all 10 of them,” Erck said.On Dec. 31, Novavax submitted its final data package to the FDA. It has yet to file the full application for emergency use authorization, but will do so shortly and expects a decision from American regulators in February.Erck didn’t name the other regulatory agencies, but according to the company site, it has recently applied for approval in Japan, the UAE, Singapore, New Zealand, Canada, Australia, South Africa and the U.K.Several other health agencies across the globe have already given their nod of approval to the vaccine.Also, on Monday, Pfizer (NYSE:PFE) CEO Albert Bourla said two doses of the company’s vaccine may not provide strong protection against Omicron COVID variant, and the original shots have also lost some of their efficacy at preventing hospitalization.In an interview at J.P. Morgan’s healthcare conference, Bourla emphasized the importance of a third shot to boost people’s protection against Omicron.“The two doses, they’re not enough for omicron,” Bourla said. “The third dose of the current vaccine is providing quite good protection against deaths, and decent protection against hospitalizations.”Earlier, Pfizer CEO said that the company will have an Omicron targeting vaccine ready in March, though he said it’s not clear whether it will be needed or not.Bourla also said he didn't know if a fourth vaccine shot would be needed but that the possibility should be studied in order to discover the best possible way to fight against the virus.","news_type":1,"symbols_score_info":{"NVAX":0.9}},"isVote":1,"tweetType":1,"viewCount":1370,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["AONE.U"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":44,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}